West Coast Financial LLC lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 35,626 shares of the company’s stock after selling 242 shares during the quarter. West Coast Financial LLC’s holdings in Johnson & Johnson were worth $5,522,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. GW&K Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $35,000. Dark Forest Capital Management LP grew its position in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after buying an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $42,000. Kepos Capital LP bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $45,000. Finally, VitalStone Financial LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $52,000. Institutional investors and hedge funds own 67.57% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on JNJ shares. Citigroup started coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. Barclays upped their target price on shares of Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Monday, July 24th. Morgan Stanley restated an “equal weight” rating and issued a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday. They issued a “strong-buy” rating for the company. Finally, Raymond James upped their target price on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research report on Monday, July 24th. Eight equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $171.80.
Johnson & Johnson Stock Down 0.3 %
JNJ stock opened at $172.40 on Thursday. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The firm has a market cap of $448.06 billion, a PE ratio of 34.90, a P/E/G ratio of 2.91 and a beta of 0.54. The firm has a 50 day simple moving average of $165.77 and a 200 day simple moving average of $161.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. During the same period in the prior year, the business earned $2.59 earnings per share. The business’s quarterly revenue was up 6.3% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.76%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Insider Activity at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Ways to Play the Upcoming NFL Season
- What is ChatGPT Stock? How to Invest in It
- The TJX Companies: Offprice Retail Hits its Stride in Q2
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Target Misses The Mark: Is It Too Late To Sell?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
